BIOSPAIN

Trade show and partnering

7 - 9 October 2025

Barcelona, Spain

PRELIMINARY PROGRAM

October 7th, 2025

09:00-09:30 h **OPENING REMARKS**

10:00 – 11:00 h **TRACK: FINANCE & INVESTMENT**
ROOM RAMÓN Y CAJAL
STARTUP PITCH PRESENTATIONS: ONCOLOGY

10:15 – 11:00 h **TRACK: LIFE SCIENCES**
AUDITORIUM Margarita Salas
Session sponsor: MSD, Columbus, Invivo, Asabys

10:15 – 11:00 h **TRACK: LIFE SCIENCES**
ROOM SEVERO OCHOA
THE ROLE OF BIOTECHNOLOGY IN THE PHARMACEUTICAL INDUSTRY, PRESENT AND FUTURE PERSPECTIVES
Session sponsor: Farmaindustria

11:00 – 11:30 h **COFFEE BREAK**

11:30 – 12:15 h **TRACK: LIFE SCIENCES**
ROOM SEVERO OCHOA
IMPLEMENTING AI IN HEALTHCARE REAL – WHAT'S HOLDING US BACK?
Session sponsor: Owkin

Abstract
AI implementation in healthcare settings. From using Real World Data and implementing AI training to deploying AI tools in healthcare.
AI has already transformed many industries, yet its full potential in healthcare remains largely untapped. While breakthroughs like large language models (LLMs) are gaining momentum, real-world deployment in hospitals and clinical settings is progressing at a slow pace. Challenges such as data governance, rigid academic frameworks, and hospitals' reluctance to adopt data-intensive solutions continue to stall AI implementation. This session will move beyond theoretical promises and future forecasts to address the real barriers preventing AI from generating more powerful tools and becoming an everyday tool in healthcare. How could we better develop AI based solutions? What needs to change? How can we drive adoption? Join us for an honest, solutions-focused discussion on making AI a reality in addressing patient needs.

11:30 – 12:15 h **TRACK: FINANCE & INVESTMENT**

ROOM RAMÓN Y CAJAL

REVERSE PITCH PRESENTATION: WHAT ARE SPANISH VC FUNDS LOOKING FOR?

Speakers:
Inveready
Swanlaab
Ysios Capital

Abstract
Understanting what VC investors want can increase your chances for success in your road show. Spanish leading biotech VCs pitch their investment models. Gain an understanding of how they value opportunities in terms of scientific risk, team credentials and experience, development plan and therapeutic areas.

11:30 – 12:15 h **TRACK: GREEN**

ROOM RAMÓN MARGALEF

MYTHS AND REALITIES OF CULTIVATED MEAT

Abstract
The roundtable discussion titled "Myths and Realities of Cultivated Meat" aims to address common misconceptions and provide factual information about cultivated meat. This session will bring together experts from various fields to discuss the scientific, technologic, economic, and social aspects of cultivated meat. The moderator, Ana Torrejón, will guide the conversation, ensuring a balanced and informative discussion.
The panelists will cover a range of topics, including the challenges of the technological processes involved in producing cultivated meat, and the opportunities for the food industry and the consumers. An engineering and equipment company will discuss the technological advancements that facilitate the production of cultivated meat. A producer of conventional meat products will provide an overview of the market trends and the company's interest in integrating cultivated meat into their product line. An expert from a company producing cultivated meat will delve into the scientific advancements and challenges in cultivated meat production. From the side of the scientific and technological development, a research centre will explain the challenges and new strategies to continue improvement in the technology of cultivated meat, as well as the consumer perception of these new products.
This roundtable aims to educate the audience, dispel myths, and foster a deeper understanding of cultivated meat as a sustainable and ethical alternative to traditional meat.

12:15 - 13:00 h **TRACK: LIFE SCIENCES**

ROOM SEVERO OCHOA

12:15 – 13:00 h **TRACK: GREEN**

ROOM RAMÓN MARGALEF

FROM FUTURE TO PRESENT THROUGH BIOTECH: ALTERNATIVE PROTEINS

Abstract

The session will provide an opportunity to showcase how biotechnology is making progress in ensuring alternative proteins are no longer alternative. While protein demand is expected to rise by around 53% by 2050, the current model of protein production is showing signs of exhaustion, incapable of responding to that increase without further compromising our planetary resources. Biotechnology provides a venue to diversify protein production with sustainable, safe, healthier foods that help us meet that growing demand. The new generation plant-based foods, cultivated meat or fermentation-made proteins and ingredients that biotechnology is making possible are also a way to address the growing concerns that consumers have about the transparency and sustainability of their food choices, helping raise their awareness.
Thanks to the participation of researchers, industry players and investors, this session will shortly analyse the current state of the alternative protein sector, the technical and industrial challenges it faces and how to address them and will provide more certainty about what the economic interest in the sector is and could be in the near future. The moderation by long-time alternative protein nonprofit GFI Europe will help stress the relevance of biotechnology in this food sector.

13:00 – 14:30 h **LUNCH BREAK**

14:30 – 15:15 h **TRACK: LIFE SCIENCES**

ROOM SEVERO OCHOA

EARLY HEALTH TECHNOLOGY ASSESSMENT: DESIGNING THE ROADMAP FOR SUCCESSFUL MEDICAL INNOVATION TRANSLATION

Session sponsor: ISCIII

Abstract

Clinical translation, the complex journey from laboratory discovery to widespread clinical practice, traditionally sees Health Technology Assessment (HTA) applied late, often post-regulatory approval. This limits its impact on early-stage development, where crucial decisions regarding technology design and research direction are made. Early HTA, however, advocates for integrating HTA principles throughout the entire translation pipeline, ensuring research aligns with real-world needs and maximizes patient benefit. This proactive approach is paramount for designing effective technology transfer roadmaps in biomedical research.
By embedding HTA early, researchers can proactively address potential barriers to adoption, moving beyond mere efficacy to consider cost-effectiveness, ethical implications, and organizational feasibility. This facilitates the alignment of research activities with clinical needs, preventing the pursuit of technologies with limited translational potential. Early engagement with stakeholders, including patients, clinicians, and payers, ensures that innovations are relevant and acceptable, fostering a collaborative approach that enhances the likelihood of successful transfer. Moreover, early HTA informs strategic decisions regarding intellectual property, regulatory pathways, and reimbursement strategies, mitigating potential market access challenges. It supports the development of robust evidence generation plans, ensuring clinical trials are designed to address key uncertainties and generate data relevant to decision-makers.
This roundtable will delve into the critical role of early HTA in shaping technology transfer roadmaps. We will count on the relevant opinions of experts in the field, who will provide diverse perspectives on the challenges and opportunities associated with integrating HTA early in the research and development process. Their insights will shed light on best practices, innovative approaches, and the potential for early HTA to drive more efficient and equitable translation of biomedical innovations.

14:30 – 15:30 h **TRACK: FINANCE & INVESTMENT**

ROOM RAMÓN Y CAJAL

STARTUP PITCH PRESENTATIONS: Medtech & IVD

14:30 – 15:15 h **TRACK: GREEN**

ROOM RAMÓN MARGALEF

15:15 – 16:00 **TRACK: LIFE SCIENCES**

AUDITORIUM Margarita Salas

15:15 – 16:00 h **TRACK: LIFE SCIENCES**

ROOM RAMÓN Y CAJAL

15:30 – 16:30 h **TRACK: GREEN**

ROOM RAMÓN MARGALEF

START UP PITCH PRESENTATIONS

21:00 – 23:00 h **WELCOME RECEPTION**

October 8th, 2025

09:15 – 10:00 h **TRACK: GREEN**

ROOM RAMÓN MARGALEF

CO2: FROM GREENHOUSE GAS EMISSION TO ADDED-VALUE PRODUCTS

Abstract

The roundtable discussion titled "Bioconversion of CO2 into Value-Added Products" aims to explore the innovative processes and technologies that convert CO2 emissions into valuable products. This session will bring together experts from various fields to discuss the scientific, economic, and environmental aspects of CO2 bioconversion.

The panelists will cover a range of topics, including the technological advancements in CO2 bioconversion, the potential environmental benefits, and the economic implications for various industries. Technologies to convert CO2 from different sources, such as combustion or anaerobic digestion, will be discussed, along with practical insights into the operation and optimization of these plants. The scientific-technological partner will delve into new technologies and processes to address different gas sources, more efficient processes and more valuable end-products.

This roundtable aims to educate the audience on the potential of CO2 bioconversion as a sustainable solution to reduce greenhouse gas emissions and produce valuable bioproducts.

09:30 – 10:15 h **TRACK: LIFE SCIENCES**

ROOM RAMON Y CAJAL

10:00 -11:00 h **TRACK: GREEN**

ROOM RAMÓN MARGALEF

START UP PITCH PRESENTATIONS

10:15 – 11:00 h **TRACK: LIFE SCIENCES**

AUDITORIUM Margarita Salas

AI IN HEALTHCARE: DRIVING INNOVATION, INVESTMENT AND REGULATION

Session sponsor: GENESIS Biomed

Moderator: **Natalia de la Figuera**, COO, GENESIS Biomed

Speakers:
Lluís Pareras, Managing partner, Invivo Capital
César Velasco, Science & Innovation Director, AstraZeneca
Xavier Canals, CEO, Tecnomed Ingenieros
Óscar Alegre, Innovation & Entrepreneurship Partner, Rousaud Costas Duran
Gustavo Fuster, European Patent Attorney, Hoffmann Eitle

Abstract
Artificial Intelligence (AI) is revolutionizing the healthcare sector, reshaping how startups, investors, and large corporations approach innovation and technology transfer. However, the path to successful AI adoption in healthcare faces critical challenges, including regulatory barriers, legal complexities, and investment hurdles.
This panel brings together key players in the ecosystem—from investors to regulatory, IP and legal experts—to discuss how AI-driven healthcare solutions can scale effectively while ensuring compliance, security, and long-term sustainability. Experts will share insights on funding trends, regulatory challenges, and corporate integration strategies, providing a 360-degree view of the future of AI in healthcare entrepreneurship.
Join us for a dynamic discussion on how AI is transforming the industry and what it takes to bridge the gap between innovation and real-world impact.

10:15 – 11:00 h **SESSION**

ROOM SEVERO OCHOA

THE ROLE OF BIOTECHNOLOGY IN THE PHARMACEUTICAL INDUSTRY, PRESENT AND FUTURE PERSPECTIVES

Sponsor: KLINEA GRUPO NET PHARMA

Abstract
The idea is to talk about the evolution of biological drugs, the current degree of penetration in the pharmaceutical industry and how we see the future.
A brief historical introduction that goes from the first recombinant drugs (insulin) to advanced therapies.
Every year there are more biotech products among the top 20 pharmaceutical blockbusters, highlighting that this year biologics are already in the majority.
In addition, in recent years, many of these blockbusters are running out of patents and therefore new biosimilars are appearing, with what is expected to be a very important line of business in the near future.
In short: we will talk about new biological drugs (main pipelines), advanced therapies and biosimilars. What is the current state of the global pharmaceutical industry and what are the future forecasts?

11:00 – 11:30 h **COFFEE BREAK**

11:30 – 12:15 h **TRACK: LIFE SCIENCE**

ROOM SEVERO OCHOA

11:30 – 12:15 h **TRACK: GREEN**

ROOM RAMÓN MARGALEF

HARNESSING NATURE: HOW SYNTHETIC BIOLOGY IS SHAPING THE BIOECONOMY

Moderator: **Fran Antequera,** Founder President, ATG SynBio Spain, France.

Abstract

Synthetic biology is redefining how we harness nature to build a sustainable bioeconomy. By integrating AI-driven predictive modeling, biomanufacturing automation, and strategic public-private collaborations, synthetic biology is enabling breakthrough innovations in biomaterials, renewable energy, agriculture, and healthcare.

This round table brings together stakeholders from startups, corporates, academia, and policy-making to explore how synthetic biology is driving tangible impact, with a focus on Spain's growing bioeconomy. The discussion will cover:

AI & Synthetic Biology (TechBio): How predictive modeling and virtual trials are accelerating bioengineering and technology transfer in healthcare and agriculture. Marc Güell will discuss how CRISPR-based therapies are revolutionizing healthcare.

Biomanufacturing & Industrial Scaling: The role of automation and microbioreactors in scaling synthetic biology solutions for biomaterials and biofuels. Maria del Mar González from Repsol will share insights on developing sustainable biofuels and circular biomaterials.

Sustainable Biotechnology and Biosolutions: Leveraging synthetic biology for a circular bioeconomy, focusing on emissions-reducing crops and regenerative agriculture. Sofie Carsten Nielsen will provide a strategic outlook on AgTech and FoodTech from the European Biosolutions Coalition.

Public-Private Collaboration and Policy Outlook: How evolving EU policies and strategic alliances are shaping the future of synthetic biology. Paul Freemont will discuss the role of biofoundries in accelerating commercialization and bridging academia and industry.

The panel will address key questions, including:

How can Spain leverage synthetic biology to lead in the European bioeconomy?

What are the latest trends in investment and public funding for synthetic biology startups?

What regulatory frameworks are needed to support growth in Europe's bioeconomy?

This session will provide attendees with strategic insights and actionable knowledge, showing how synthetic biology and TechBio are catalyzing the bioeconomy and positioning Spain and Europe as leaders in sustainable biotechnology.

12:15 – 13:00 h **TRACK: LIFE SCIENCES**

AUDITORIUM Margarita Salas

NAVIGATING THE TRANSITION FROM IVDD TO IVDR

Session sponsor: Asphalion

Moderator: **Francisco Rodriguez**, Medical Device Manager, Asphalion, Spain.

Speakers:
Walter Sanseverino, CEO, Sequentia Biotech SL, Spain.
María Teresa Gómez Manzano, Medical Devices Manager Spain/Medical Devices Lead Auditor, SGS, Spain)
Talyta Carteano, Director of Unit Medtech, Asphalion, Spain
Josefa Güiles, Associate Director of Unit Medtech, Asphalion, Spain

Abstract

This session provides an overview of the European Union's In Vitro Diagnostic Regulation (IVDR), its impact on the IVDD industry, and the regulatory path defined by the new regulation.
We will be able to detail the critical differences between the IVDD and IVDR, highlight the challenges associated with the transition, and explain the specific transition periods and conditions outlined by the regulation.
We will discuss the necessary steps manufacturers must take to comply with the Regulation (2024/1860), including quality management, technical documentation, and post-market surveillance.
The session will feature a Notified Body, a manufacturer, and a consultant, who will give us diverse perspectives on their roles and share valuable experiences on the transition to the IVDR.

12:15 – 13:00 h **SESSION**

ROOM SEVERO OCHOA

Abstract

The TIMEBASE-INTREPIBD study harnessed wearable technology to continuously monitor physiological markers in bipolar disorder patients, revealing distinct digital biomarkers across mood states. Using deep learning and self-supervised models, the research achieved up to 85% accuracy in automated symptom detection, paving the way for objective monitoring and personalized intervention in BD. Results from the study will be presented, highlighting how wearable technology captured digital biomarkers in bipolar disorder to differentiate mood states.
To explore the validity of the spontaneous speech analysis system "AcceXible" for the correct screening of depression in adults and to evaluate at short-term follow-up the variability in speech characteristics among participants and their relationship with clinical variables that are not obtained with conventional psychometric assessment.
The results of a study of suicide risk prediction (suicide attempt and completed suicide) by applying artificial intelligence (AI) predictive models to the integrated medical records of about 40.000 patients over five years are presented.
By integrating advanced predictive models into routine clinical workflows, IDICIUS has the potential to improve early identification, guide timely interventions and potentially contribute to suicide prevention.

- A Multi-Modal Approach Using Wearable Technology for State Detection in Bipolar Disorder: The TIMEBASE-INTREPIBD study.
- Exploratory study of the AcceXible screening and follow-up system for patients with depression.
- Development of AI algorithms trained with real-world data for suicide risk prevention in pediatric and adult patients: IDICIUS project.

12:15 – 13:00 h **TRACK: FINANCE & INVESTMENT**

ROOM RAMÓN Y CAJAL

12:15 – 13:00 h **TRACK: GREEN**

ROOM RAMÓN MARGALEF

13:00 – 14:30 h **LUNCH BREAK**

14:30 – 15:15 h **TRACK: LIFE SCIENCES**

AUDITORIUM Margarita Salas

14:30 – 15:15 h **TRACK: LIFE SCIENCES**

ROOM SEVERO OCHOA

Abstract

The access of healthcare technologies to the market requires a prior validation which implies regulatory and data protection issues.

In this roundtable, our goal is to analyze and discuss on the current applicable regulations, both nationally and internationally, applicable to the validation of healthcare technologies to understand the complex framework a company has to deal with in order to access the market in Spain. We will approach this topic from two fundamental perspectives:

1. Regulatory: We will delve into the regulations governing medical and healthcare technologies, evaluating their impact and the requirements they impose to ensure the safety and efficacy of these technologies.

2. Data Protection and Security: We will examine the implications related to data protection, cybersecurity, and information security. Additionally, we will discuss best practices in the development of IT solutions and software applications, ensuring they meet the highest standards of security and privacy.

14:30 – 15:30 h **TRACK: FINANCE & INVESTMENT**

ROOM RAMÓN Y CAJAL

15:15 – 16:00 h **TRACK: LIFE SCIENCES**

AUDITORIUM Margarita Salas

15:30 – 16:15 h **TRACK: FINANCE & INVESTMENT**

ROOM RAMÓN Y CAJAL

DUE DILIGENCE DECODED: DIVING INTO VC, CVC, AND PHARMA PRACTICES

Moderator: **Francisco Oliveira Peixoto**

16:00 – 16:45 h **TRACK: LIFE SCIENCES**

AUDITORIUM Margarita Salas

19:00 – 23:00 h **TAPAS ROUTE**

October 9th, 2025

09:00 – 11:00 h **TRACK: LIFE SCIENCE**

ROOM SEVERO OCHOA

PRESENTATION OF ARISTOS PROJECT

Session sponsor: ISCIII